JP2017533276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533276A5 JP2017533276A5 JP2017542498A JP2017542498A JP2017533276A5 JP 2017533276 A5 JP2017533276 A5 JP 2017533276A5 JP 2017542498 A JP2017542498 A JP 2017542498A JP 2017542498 A JP2017542498 A JP 2017542498A JP 2017533276 A5 JP2017533276 A5 JP 2017533276A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- thc
- patient
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 47
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 47
- 229960004242 dronabinol Drugs 0.000 claims description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 230000007000 age related cognitive decline Effects 0.000 claims description 11
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 8
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 8
- 229950011318 cannabidiol Drugs 0.000 claims description 8
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 8
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 8
- 229930003827 cannabinoid Natural products 0.000 claims description 6
- 239000003557 cannabinoid Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000007792 alzheimer disease pathology Effects 0.000 claims description 2
- 229940065144 cannabinoids Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000003920 cognitive function Effects 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 208000028329 epileptic seizure Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 240000004308 marijuana Species 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000006996 mental state Effects 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 36
- 239000003708 ampul Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- -1 vial Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462074134P | 2014-11-03 | 2014-11-03 | |
| US62/074,134 | 2014-11-03 | ||
| PCT/IB2015/058453 WO2016071819A1 (en) | 2014-11-03 | 2015-11-02 | Methods for treatment of cognitive decline |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533276A JP2017533276A (ja) | 2017-11-09 |
| JP2017533276A5 true JP2017533276A5 (https=) | 2018-10-25 |
| JP6676062B2 JP6676062B2 (ja) | 2020-04-08 |
Family
ID=55908668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542498A Expired - Fee Related JP6676062B2 (ja) | 2014-11-03 | 2015-11-02 | 認知低下を処置するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10660872B2 (https=) |
| EP (1) | EP3215148B1 (https=) |
| JP (1) | JP6676062B2 (https=) |
| CN (1) | CN106999467A (https=) |
| AU (2) | AU2015341458B2 (https=) |
| CA (1) | CA2966710A1 (https=) |
| WO (1) | WO2016071819A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033493B2 (en) | 2013-12-02 | 2021-06-15 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
| US11065225B1 (en) * | 2015-07-30 | 2021-07-20 | University Of South Florida | Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease |
| US11446276B2 (en) | 2015-07-30 | 2022-09-20 | University Of South Florida | Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease |
| GB2549277B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| BR112020019768A2 (pt) | 2018-03-30 | 2021-01-26 | India Globalization Capital, Inc. | método e composição para o tratamento de distúrbios do sistema nervoso central (snc) |
| GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| US10828254B2 (en) | 2018-09-28 | 2020-11-10 | Intelgenx Corp. | Oral film formulation for modulating absorption profile |
| US11602504B2 (en) | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
| US12303501B2 (en) | 2018-11-05 | 2025-05-20 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CN114650809A (zh) | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| CA3155176A1 (en) | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
| CA3155181A1 (en) | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal delivery of cannabidiol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP2025512495A (ja) | 2022-04-12 | 2025-04-17 | シャッケルフォード・ファーマ・インコーポレーテッド | 発作性障害の治療 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804592A (en) * | 1997-05-30 | 1998-09-08 | Unimed Pharmaceuticals, Inc. | Method for improving disturbed behavior and elevating mood in humans |
| US6509005B1 (en) | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
| US7648696B2 (en) | 1999-08-20 | 2010-01-19 | Unimed Pharmaceuticals, Llc | Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
| US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
| US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| WO2008019146A2 (en) * | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| US8039509B2 (en) | 2006-11-10 | 2011-10-18 | Johnson Matthey Public Limited Company | Composition comprising (−)-Δ9-trans-tetrahydrocannabinol |
| EP2341903A1 (en) * | 2008-07-31 | 2011-07-13 | Bionorica Research GmbH | Cannabinoids for use in treating or preventing cognitive impairment and dementia |
| WO2012068516A2 (en) | 2010-11-18 | 2012-05-24 | Pier Pharmaceuticals | Low dose cannabinoid medicaments |
| GB2524469A (en) | 2014-02-14 | 2015-09-30 | Kind Consumer Ltd | A cannabinoid inhaler and composition therefor |
-
2015
- 2015-11-02 JP JP2017542498A patent/JP6676062B2/ja not_active Expired - Fee Related
- 2015-11-02 EP EP15856362.7A patent/EP3215148B1/en not_active Not-in-force
- 2015-11-02 CA CA2966710A patent/CA2966710A1/en not_active Abandoned
- 2015-11-02 US US15/523,934 patent/US10660872B2/en not_active Expired - Fee Related
- 2015-11-02 WO PCT/IB2015/058453 patent/WO2016071819A1/en not_active Ceased
- 2015-11-02 CN CN201580066475.3A patent/CN106999467A/zh active Pending
- 2015-11-02 AU AU2015341458A patent/AU2015341458B2/en not_active Ceased
-
2020
- 2020-11-13 AU AU2020267285A patent/AU2020267285A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533276A5 (https=) | ||
| JP6615277B2 (ja) | Ｒ−ケタミンおよびその塩の医薬品としての応用 | |
| US7968594B2 (en) | Pharmaceutical compositions for the treatment of pain | |
| ES2894836T3 (es) | Compuestos de CBD fluorados, composiciones y usos de los mismos | |
| US20060135599A1 (en) | Use for pharmaceutical composition | |
| JP2009539961A5 (https=) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| Voshaar et al. | A randomized study of tiotropium Respimat® Soft MistTM Inhaler vs. ipratropium pMDI in COPD | |
| JP2011500781A5 (https=) | ||
| Kaufman | Pharmaceutical approval update | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| US20200289460A1 (en) | Cannabinoid compositions and methods of use thereof | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| CA3026770C (en) | Andrographolide treats progressive forms of multiple sclerosis | |
| ITMI20121317A1 (it) | Composizioni per il trattamento della fatica oncologica | |
| Sarkhosh et al. | Effectiveness of Chamomile in Reducing the Incidence and Severity of Nausea and Vomiting After Middle Ear Surgery: A Triple-Blind Randomized Study | |
| RU2013141926A (ru) | Терапевтическое применение димирацетама для предотвращения ладонно-подошвенного синдрома, вызываемого сорафенибом | |
| HK40069995A (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| CN103933034B (zh) | 一种含有木犀草素的药物组合物及应用 | |
| CN103417549B (zh) | 化合物在制备升高红细胞药物中的应用 | |
| CN113332333A (zh) | 抗covid-19病毒的黄芩茎叶总黄酮 | |
| McIver et al. | P6 Fluticasone Propionate/Formoterol Fumarate Combination Therapy Has an Efficacy Profile Similar to That of Its Individual Components Administered Concurrently | |
| RU2012123302A (ru) | Лекарственное средство, предупреждающее предрак и рак простаты, фармацевтическая композиция, активный ингредиент фармацевтической композиции и способ химиопрофилактики рака простаты | |
| CN103599104B (zh) | Caesanines D在制备治疗口腔溃疡药物中的应用 |